Horizon Pharma (NASDAQ:HZNP) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.
HZNP has been the topic of a number of other reports. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and increased their price target for the stock from $12.00 to $18.00 in a report on Friday, January 12th. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a report on Wednesday, December 27th. Jefferies Group increased their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. UBS Group set a $20.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. Finally, ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $19.25.
Shares of Horizon Pharma (HZNP) traded up $0.14 during midday trading on Wednesday, reaching $14.03. 533,163 shares of the company were exchanged, compared to its average volume of 1,679,981. Horizon Pharma has a 12-month low of $9.45 and a 12-month high of $17.69. The stock has a market capitalization of $2,270.00, a P/E ratio of -4.61, a PEG ratio of 0.65 and a beta of 1.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52.
Several large investors have recently bought and sold shares of the company. William Blair Investment Management LLC lifted its stake in shares of Horizon Pharma by 12.2% in the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock worth $128,861,000 after buying an additional 958,414 shares in the last quarter. Sterling Capital Management LLC purchased a new position in shares of Horizon Pharma in the fourth quarter worth about $1,340,000. Segall Bryant & Hamill LLC lifted its stake in shares of Horizon Pharma by 12.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock worth $10,585,000 after buying an additional 81,074 shares in the last quarter. Redmile Group LLC acquired a new stake in Horizon Pharma during the fourth quarter worth about $292,000. Finally, Cowen Inc. acquired a new stake in Horizon Pharma during the fourth quarter worth about $781,000. 84.39% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/21/bidaskclub-downgrades-horizon-pharma-hznp-to-sell.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.